1. Home
  2. Labeler Index
  3. Bryant Ranch Prepack
  4. 63629-7516
  5. Product Images: Levetiracetam

Product Images Levetiracetam

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 11 images provide visual information about the product associated with Levetiracetam NDC 63629-7516 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 02

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 02

The given text provides formulas for calculating two medical parameters: estimated creatinine clearance (CrCl) and serum creatinine. The first formula measures the CrCl, which is determined by taking 140 and subtracting the patient's age (in years) before multiplying the result by the patient's weight (in kilograms). For female patients, the final result should be multiplied by 0.85. The second formula calculates serum creatinine using a value of 72 and the patient's serum creatinine level (in mg/dL).*

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 03

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 03

Levetiracetam Structural Formula - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 04

Levetiracetam Structural Formula - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 04

Figure 1: Responder Rate (greater than or equal to 50% Reduction from Baseline) in Study 1 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 05

Figure 1: Responder Rate (greater than or equal to 50% Reduction from Baseline) in Study 1 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 05

The text describes a figure titled "Responder Rate (>50% Reduction From Baseline) In Study 1", which shows the percentage of responders against placebo and different doses of Levetiracetam (1000 mg/day and 3000 mg/day). It also indicates that the higher dose of 3000 mg/day was statistically significant compared to the placebo.*

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 06

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 06

This is a graph showing the responder rate in Study 2 for a period of time. The responder rate is represented as (>50% Reduction From Baseline). The graph compares the effectiveness of a Placebo versus two different doses of Levetiracetam. Levetiracetam at a dose of 1000 mg/day had a responder rate of 20%, while Levetiracetam at a dose of 2000 mg/day had a responder rate of 35%. The text also indicates that the difference between the Levetiracetam doses and the Placebo was statistically significant.*

Figure 3: Responder Rate (greater than or equal to 50% Reduction from Baseline) in Study 3 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 07

Figure 3: Responder Rate (greater than or equal to 50% Reduction from Baseline) in Study 3 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 07

This is a chart showing the Responder Rate, which is the percentage of participants who experienced at least a 50% reduction in symptoms compared to their baseline, in Study 3. The chart compares the placebo group (with 104 participants) to the group taking 3000 mg/day of Levetiracetam (with 180 participants). Levetiracetam was found to be statistically significant compared to the placebo.*

Figure 4: Responder Rate (greater than or equal to 50% Reduction from Baseline) - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 08

Figure 4: Responder Rate (greater than or equal to 50% Reduction from Baseline) - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 08

The figure 4 shows the Responder Rate in Study 4 with reduction from baseline. The graph includes percentages ranging from 5% to 446%. The study included a Placebo group with N=97 and a Levetiracetam group with N=101. The Levetiracetam group showed a statistically significant result as compared to Placebo.*

figure 5 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 09

figure 5 - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 09

The text is not available for generating a useful description.*

Figure 6: Responder Rate (greater than or equal to 50% Reduction from Baseline) in PGTC Seizure Frequency per Week - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 10

Figure 6: Responder Rate (greater than or equal to 50% Reduction from Baseline) in PGTC Seizure Frequency per Week - f7b86151 8fdf 4bb8 8cd6 e6e24786df64 10

The figure 6 shows the responder rate of patients suffering from PGTC seizure frequency per week in Study 7. The graph shows the percentage of patients who had at least a 50% reduction from baseline in seizure frequency. The placebo group (N=84) had a responder rate of 45.2%, while the Levetiracetam group had a responder rate of 72.2%, which is statistically significant when compared to placebo.*

image 01

image 01

Label Image - lbl636297516

Label Image - lbl636297516

This is a comparison between a medication, Keppra 1000mg Tablet made by Zhejiang Huahai Pharma Co Ltd, and an unidentified drug packaged by Bryant Ranck Prepack. The unidentified drug is a pack of 30 tablets with an expiration date of MM/YY and NDC number 6362975161. The manufacturer's address is also provided. The drug should be stored at room temperature, and caution should be taken to keep all drugs out of reach of children.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.